Thirona Bio, MannKind Team for Potential New IPF InhaledTherapy

Thirona Bio, MannKind Team for Potential New IPF InhaledTherapy

297254

Thirona Bio, MannKind Team for Potential New IPF InhaledTherapy

Thirona Bio has teamed with MannKind Corporation to develop and test a potential inhaled treatment for fibrotic lung diseases, including idiopathic pulmonary fibrosis (IPF). FBM5712, which Thirona is working to advance as a possible topical treatment of skin fibrosis, will be modified and investigated by MannKind for its potential as a dry-powder therapy for fibrotic disorders of the lungs. “This collaboration with MannKind gives Thirona the opportunity to potentially expand the development of FBM5712 into fibrotic…

You must be logged in to read/download the full post.